Labcorp Holdings Inc. (NYSE:LH) Announces Quarterly Dividend of $0.72

Labcorp Holdings Inc. (NYSE:LH) declared a quarterly dividend on Thursday, July 9th. Stockholders of record on Friday, August 28th will be paid a dividend of 0.72 per share by the medical research company on Friday, September 11th. This represents a c) dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date is Friday, August 28th.

Labcorp has a dividend payout ratio of 16.4% meaning its dividend is sufficiently covered by earnings. Analysts expect Labcorp to earn $19.33 per share next year, which means the company should continue to be able to cover its $2.88 annual dividend with an expected future payout ratio of 14.9%.

Labcorp Trading Down 0.1%

NYSE LH opened at $277.51 on Friday. Labcorp has a 52 week low of $241.81 and a 52 week high of $293.72. The company has a 50 day moving average price of $263.69 and a 200 day moving average price of $267.01. The company has a quick ratio of 1.54, a current ratio of 1.73 and a debt-to-equity ratio of 0.68. The firm has a market cap of $22.76 billion, a PE ratio of 24.58, a price-to-earnings-growth ratio of 1.94 and a beta of 0.89.

Labcorp (NYSE:LH) last announced its earnings results on Thursday, April 30th. The medical research company reported $4.25 earnings per share for the quarter, beating the consensus estimate of $4.09 by $0.16. Labcorp had a net margin of 6.66% and a return on equity of 16.29%. The company had revenue of $3.54 billion during the quarter, compared to the consensus estimate of $3.51 billion. During the same period last year, the firm earned $3.84 earnings per share. Labcorp’s revenue was up 5.8% compared to the same quarter last year. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. As a group, sell-side analysts forecast that Labcorp will post 18 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently commented on the company. Weiss Ratings reiterated a “buy (b-)” rating on shares of Labcorp in a report on Friday, May 8th. Robert W. Baird set a $334.00 target price on Labcorp in a research note on Friday, May 1st. Evercore reaffirmed an “outperform” rating and set a $300.00 target price on shares of Labcorp in a research report on Wednesday, April 8th. Finally, Wall Street Zen cut Labcorp from a “buy” rating to a “hold” rating in a research note on Saturday, June 13th. Eight equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $313.33.

Labcorp Company Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.